Loading…
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study
We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with a...
Saved in:
| Published in: | Leukemia & lymphoma 2022-01, Vol.63 (2), p.416-425 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c314t-ac293ce2da0cf1aeaf273f89847fb819541316b3e93651f47ac66a3b309bc3c83 |
| container_end_page | 425 |
| container_issue | 2 |
| container_start_page | 416 |
| container_title | Leukemia & lymphoma |
| container_volume | 63 |
| creator | Gjærde, Lars Klingen Rank, Cecilie Utke Andersen, Mette Klarskov Jakobsen, Lasse Hjort Sengeløv, Henrik Olesen, Gitte Kornblit, Brian Marquart, Hanne Friis, Lone Smidstrup Petersen, Søren Lykke Andersen, Niels Smedegaard Nielsen, Ove Juul Toft, Nina Schjødt, Ida |
| description | We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27-66%) in year 2000 versus 77% (CI 59-88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00-1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93-1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87-0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93-1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure. |
| doi_str_mv | 10.1080/10428194.2021.1992620 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34672245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2585413631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-ac293ce2da0cf1aeaf273f89847fb819541316b3e93651f47ac66a3b309bc3c83</originalsourceid><addsrcrecordid>eNp9kEtv1DAURi1UREvhJ4C87CaDX8nErFqVV6VKbOjaunHs1uDEwY9Bs-G31-lMWbLylXy-e_UdhN5RsqGkJx8oEaynUmwYYXRDpWQdIy_QGSVMNkwQfrLOgjUrdIpep_STENLKjr1Cp1x0W8ZEe4b-3kxLDDsz4lTizu3AY7DZRAzeh3szG6dxjjCnxcOcIbswYxvqty7ZYL-flocweEi5ct6UX2ZygN2MYSw-p48Y8CeYXXrAS1iKf8o3A6T1Xi7j_g16acEn8_b4nqO7L59_XH9rbr9_vbm-um00pyI3oJnk2rARiLYUDFi25baXvdjaoRZsBeW0G7iRvGupFVvQXQd84EQOmuuen6OLw95a9ncxKavJJW18LWVCSYq1_bqj47Si7QHVMaQUjVVLdBPEvaJErerVs3q1qldH9TX3_niiDJMZ_6WeXVfg8gC4uRqc4E-IflQZ9j5EWxVrlxT__41HmYqVwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2585413631</pqid></control><display><type>article</type><title>Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Gjærde, Lars Klingen ; Rank, Cecilie Utke ; Andersen, Mette Klarskov ; Jakobsen, Lasse Hjort ; Sengeløv, Henrik ; Olesen, Gitte ; Kornblit, Brian ; Marquart, Hanne ; Friis, Lone Smidstrup ; Petersen, Søren Lykke ; Andersen, Niels Smedegaard ; Nielsen, Ove Juul ; Toft, Nina ; Schjødt, Ida</creator><creatorcontrib>Gjærde, Lars Klingen ; Rank, Cecilie Utke ; Andersen, Mette Klarskov ; Jakobsen, Lasse Hjort ; Sengeløv, Henrik ; Olesen, Gitte ; Kornblit, Brian ; Marquart, Hanne ; Friis, Lone Smidstrup ; Petersen, Søren Lykke ; Andersen, Niels Smedegaard ; Nielsen, Ove Juul ; Toft, Nina ; Schjødt, Ida</creatorcontrib><description>We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27-66%) in year 2000 versus 77% (CI 59-88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00-1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93-1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87-0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93-1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.1080/10428194.2021.1992620</identifier><identifier>PMID: 34672245</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>acute lymphoblastic leukemia ; Adolescent ; Adult ; Aged ; ALL ; allogeneic hematopoietic stem cell transplantation ; Allogeneic transplantation ; Cohort Studies ; Denmark - epidemiology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Retrospective Studies ; survival ; Transplantation Conditioning ; Transplantation, Homologous ; Young Adult</subject><ispartof>Leukemia & lymphoma, 2022-01, Vol.63 (2), p.416-425</ispartof><rights>2021 Informa UK Limited, trading as Taylor & Francis Group 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c314t-ac293ce2da0cf1aeaf273f89847fb819541316b3e93651f47ac66a3b309bc3c83</cites><orcidid>0000-0002-5496-9955</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34672245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gjærde, Lars Klingen</creatorcontrib><creatorcontrib>Rank, Cecilie Utke</creatorcontrib><creatorcontrib>Andersen, Mette Klarskov</creatorcontrib><creatorcontrib>Jakobsen, Lasse Hjort</creatorcontrib><creatorcontrib>Sengeløv, Henrik</creatorcontrib><creatorcontrib>Olesen, Gitte</creatorcontrib><creatorcontrib>Kornblit, Brian</creatorcontrib><creatorcontrib>Marquart, Hanne</creatorcontrib><creatorcontrib>Friis, Lone Smidstrup</creatorcontrib><creatorcontrib>Petersen, Søren Lykke</creatorcontrib><creatorcontrib>Andersen, Niels Smedegaard</creatorcontrib><creatorcontrib>Nielsen, Ove Juul</creatorcontrib><creatorcontrib>Toft, Nina</creatorcontrib><creatorcontrib>Schjødt, Ida</creatorcontrib><title>Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27-66%) in year 2000 versus 77% (CI 59-88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00-1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93-1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87-0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93-1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.</description><subject>acute lymphoblastic leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>ALL</subject><subject>allogeneic hematopoietic stem cell transplantation</subject><subject>Allogeneic transplantation</subject><subject>Cohort Studies</subject><subject>Denmark - epidemiology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Retrospective Studies</subject><subject>survival</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Homologous</subject><subject>Young Adult</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kEtv1DAURi1UREvhJ4C87CaDX8nErFqVV6VKbOjaunHs1uDEwY9Bs-G31-lMWbLylXy-e_UdhN5RsqGkJx8oEaynUmwYYXRDpWQdIy_QGSVMNkwQfrLOgjUrdIpep_STENLKjr1Cp1x0W8ZEe4b-3kxLDDsz4lTizu3AY7DZRAzeh3szG6dxjjCnxcOcIbswYxvqty7ZYL-flocweEi5ct6UX2ZygN2MYSw-p48Y8CeYXXrAS1iKf8o3A6T1Xi7j_g16acEn8_b4nqO7L59_XH9rbr9_vbm-um00pyI3oJnk2rARiLYUDFi25baXvdjaoRZsBeW0G7iRvGupFVvQXQd84EQOmuuen6OLw95a9ncxKavJJW18LWVCSYq1_bqj47Si7QHVMaQUjVVLdBPEvaJErerVs3q1qldH9TX3_niiDJMZ_6WeXVfg8gC4uRqc4E-IflQZ9j5EWxVrlxT__41HmYqVwQ</recordid><startdate>20220128</startdate><enddate>20220128</enddate><creator>Gjærde, Lars Klingen</creator><creator>Rank, Cecilie Utke</creator><creator>Andersen, Mette Klarskov</creator><creator>Jakobsen, Lasse Hjort</creator><creator>Sengeløv, Henrik</creator><creator>Olesen, Gitte</creator><creator>Kornblit, Brian</creator><creator>Marquart, Hanne</creator><creator>Friis, Lone Smidstrup</creator><creator>Petersen, Søren Lykke</creator><creator>Andersen, Niels Smedegaard</creator><creator>Nielsen, Ove Juul</creator><creator>Toft, Nina</creator><creator>Schjødt, Ida</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5496-9955</orcidid></search><sort><creationdate>20220128</creationdate><title>Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study</title><author>Gjærde, Lars Klingen ; Rank, Cecilie Utke ; Andersen, Mette Klarskov ; Jakobsen, Lasse Hjort ; Sengeløv, Henrik ; Olesen, Gitte ; Kornblit, Brian ; Marquart, Hanne ; Friis, Lone Smidstrup ; Petersen, Søren Lykke ; Andersen, Niels Smedegaard ; Nielsen, Ove Juul ; Toft, Nina ; Schjødt, Ida</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-ac293ce2da0cf1aeaf273f89847fb819541316b3e93651f47ac66a3b309bc3c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>acute lymphoblastic leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>ALL</topic><topic>allogeneic hematopoietic stem cell transplantation</topic><topic>Allogeneic transplantation</topic><topic>Cohort Studies</topic><topic>Denmark - epidemiology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Retrospective Studies</topic><topic>survival</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Homologous</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gjærde, Lars Klingen</creatorcontrib><creatorcontrib>Rank, Cecilie Utke</creatorcontrib><creatorcontrib>Andersen, Mette Klarskov</creatorcontrib><creatorcontrib>Jakobsen, Lasse Hjort</creatorcontrib><creatorcontrib>Sengeløv, Henrik</creatorcontrib><creatorcontrib>Olesen, Gitte</creatorcontrib><creatorcontrib>Kornblit, Brian</creatorcontrib><creatorcontrib>Marquart, Hanne</creatorcontrib><creatorcontrib>Friis, Lone Smidstrup</creatorcontrib><creatorcontrib>Petersen, Søren Lykke</creatorcontrib><creatorcontrib>Andersen, Niels Smedegaard</creatorcontrib><creatorcontrib>Nielsen, Ove Juul</creatorcontrib><creatorcontrib>Toft, Nina</creatorcontrib><creatorcontrib>Schjødt, Ida</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gjærde, Lars Klingen</au><au>Rank, Cecilie Utke</au><au>Andersen, Mette Klarskov</au><au>Jakobsen, Lasse Hjort</au><au>Sengeløv, Henrik</au><au>Olesen, Gitte</au><au>Kornblit, Brian</au><au>Marquart, Hanne</au><au>Friis, Lone Smidstrup</au><au>Petersen, Søren Lykke</au><au>Andersen, Niels Smedegaard</au><au>Nielsen, Ove Juul</au><au>Toft, Nina</au><au>Schjødt, Ida</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2022-01-28</date><risdate>2022</risdate><volume>63</volume><issue>2</issue><spage>416</spage><epage>425</epage><pages>416-425</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27-66%) in year 2000 versus 77% (CI 59-88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00-1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93-1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87-0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93-1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>34672245</pmid><doi>10.1080/10428194.2021.1992620</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5496-9955</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 2022-01, Vol.63 (2), p.416-425 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_pubmed_primary_34672245 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | acute lymphoblastic leukemia Adolescent Adult Aged ALL allogeneic hematopoietic stem cell transplantation Allogeneic transplantation Cohort Studies Denmark - epidemiology Hematopoietic Stem Cell Transplantation - adverse effects Humans Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Retrospective Studies survival Transplantation Conditioning Transplantation, Homologous Young Adult |
| title | Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A00%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20survival%20after%20allogeneic%20transplantation%20for%20acute%20lymphoblastic%20leukemia%20in%20adults:%20a%20Danish%20population-based%20study&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Gj%C3%A6rde,%20Lars%20Klingen&rft.date=2022-01-28&rft.volume=63&rft.issue=2&rft.spage=416&rft.epage=425&rft.pages=416-425&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.1080/10428194.2021.1992620&rft_dat=%3Cproquest_pubme%3E2585413631%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c314t-ac293ce2da0cf1aeaf273f89847fb819541316b3e93651f47ac66a3b309bc3c83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2585413631&rft_id=info:pmid/34672245&rfr_iscdi=true |